13F Holdings
中文EN

OTLK Outlook Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649989 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-40.7%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin195.6%
Operating margin4,781.8%
Net margin5,253.5%
FCF margin—
EBITDA margin4,772.9%

Returns

ROE—
ROA-251.7%
ROIC (approx.)—
Asset turnover-0.05x

Leverage & solvency

Liabilities / assets139.7%
Debt / equity—
Current ratio0.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-20.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue$1.41M————
Cost of revenue$1.36M————
Gross profit$57,205————
R&D expense$27.18M$41.76M$26.45M$42.33M$38.96M
SG&A expense$39.94M$29.94M$26.67M$20.74M$12.77M
Operating income-$67.06M-$71.70M-$53.13M-$63.07M-$51.73M
Interest expense—$3.16M$2.53M——
Pretax income-$63.98M-$75.36M-$58.98M-$66.05M-$53.16M
Income tax-$1.55M$2,800$2,800$2,800$2,000
Net income-$62.42M-$75.37M-$58.98M-$66.05M-$53.16M
EBITDA-$66.94M-$71.59M-$53.08M-$62.87M-$51.46M
EPS (basic)-1.79-4.06-4.72-0.31-0.35
EPS (diluted)-1.79-4.06-4.72-0.31-0.35
Weighted avg. shares (diluted)34.80M18.55M12.51M212.08M152.68M
Banking
Net interest income-$283,128-$3.16M-$1.56M-$1.49M-$936,127
Balance sheet
Cash & equivalents$8.08M$14.93M$23.39M$17.40M$14.48M
Receivables$1.49M————
Inventory$3.34M————
Current assets$17.39M$27.42M$30.98M$27.52M$21.51M
PP&E, net————$163,625
Total assets$18.58M$28.82M$32.30M$28.53M$22.81M
Current liabilities$45.81M$42.55M$46.73M$19.73M$6.75M
Total liabilities$50.77M$101.90M$46.74M$19.79M$18.20M
Shareholders' equity-$32.19M-$73.08M-$14.44M$8.74M$4.61M
Shares outstanding53.89M23.91M13.01M227.31M176.46M
Cash flow statement
Operating cash flow-$51.83M-$68.79M-$42.97M-$56.67M-$54.25M
Financing cash flow$44.98M$60.33M$48.97M$59.59M$56.19M
Depreciation & amortization$117,052$113,859$44,188$204,694$262,140
Stock-based compensation$8.90M$5.39M$5.55M$7.71M$4.89M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.